Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE) (MUSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02637232
Recruitment Status : Completed
First Posted : December 22, 2015
Last Update Posted : May 18, 2016
Sponsor:
Collaborator:
Chiltern International Inc.
Information provided by (Responsible Party):
Galderma

Tracking Information
First Submitted Date December 16, 2015
First Posted Date December 22, 2015
Last Update Posted Date May 18, 2016
Study Start Date October 2015
Actual Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: December 21, 2015)
Satisfaction among patients to whom Mirvaso®/OnrelteaTM is prescribed (% of subjects across score per question). [ Time Frame: Week 4 ]
% of subjects across score per question.
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT02637232 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)
Official Title Mirvaso® Utilisation and Patient Satisfaction Evaluation
Brief Summary The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.
Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population patient with persistent facial erythema of rosacea
Condition Rosacea
Intervention Other: Mirvaso® / Onreltea TM
Study Groups/Cohorts Mirvaso® / Onreltea TM
Intervention: Other: Mirvaso® / Onreltea TM
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: April 26, 2016)
302
Original Estimated Enrollment
 (submitted: December 21, 2015)
330
Actual Study Completion Date May 2016
Actual Primary Completion Date May 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients to whom the physician has already decided to prescribe Mirvaso® /OnrelteaTM according to package insert
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT02637232
Other Study ID Numbers RD.03.SPR.104160
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Galderma
Study Sponsor Galderma
Collaborators Chiltern International Inc.
Investigators Not Provided
PRS Account Galderma
Verification Date May 2016